Vanda Pharmaceuticals Announces EMA Positive Opinion for Orphan Drug Designation of Imsidolimab for Generalized Pustular Psoriasis - A Milestone Recognition of GPP as a Distinct Rare Disease in Europe

RegulatorypositiveimsidolimabPositive

AI Analysis

Summary

Vanda Pharmaceuticals announced a positive opinion from the EMA Committee for Orphan Medicinal Products recommending orphan drug designation for imsidolimab in generalized pustular psoriasis, marking regulatory recognition of GPP as a distinct rare disease in Europe.

Outcome Details

EMA Committee for Orphan Medicinal Products adopted positive opinion recommending orphan drug designation

Importance:6/10

Sentiment:

0.80

orphan drug designationEMAregulatory milestonerare diseaseimsidolimabgeneralized pustular psoriasis

Related Companies

$VNDA

Read the original article

Published by PR Newswire Pharma on July 16, 2026 8:30 PM

Read Original